GLP-1 Receptor AgonistPrescription OnlyPregnancy Cat. Not classifiedFDA 2017
Semaglutide (Oral)
semaglutide
Semaglutide is a GLP-1 receptor agonist used to improve glycemic control in adults with type 2 diabetes and to reduce the risk of major cardiovascular events. The oral formulation (Rybelsus) and injectable formulation (Ozempic) share the same active ingredient.
Medically reviewed by MedCentralHub Medical Review Board, Licensed Pharmacists & Physicians ·
Brand names:RybelsusOzempic
Quick Reference
Medicine ClassGLP-1 Receptor Agonist
FDA Approved2017
PregnancyCategory Not classified
FormsOral tablet (Rybelsus), Subcutaneous injection pen (Ozempic)
Quick Facts
- Active ingredient
- semaglutide
- Medicine class
- GLP-1 Receptor Agonist
- Brand names
- Rybelsus·Ozempic
- Availability
- Prescription only (Rx)
- Pregnancy category
- Not classified
- Half-life
- Approximately 7 days (both oral and injectable formulations).
- Major interactions
- InsulinMajor·Other GLP-1 receptor agonists (liraglutide, dulaglutide, exenatide)Major
- FDA approved
- 2017
What Is Semaglutide (Oral)?
Semaglutide is a GLP-1 receptor agonist used to improve glycemic control in adults with type 2 diabetes and to reduce the risk of major cardiovascular events. The oral formulation (Rybelsus) and injectable formulation (Ozempic) share the same active ingredient.
Semaglutide (Oral) (semaglutide) belongs to the GLP-1 Receptor Agonist class of medications. It was first approved by the FDA in 2017. This medication requires a prescription from a licensed healthcare provider.
Key Safety Information
- •Always follow the dose recommended by your healthcare professional. Taking more than prescribed increases the risk of side effects including serious complications.
- •Seek emergency care if you experience signs of an allergic reaction — hives, swelling, difficulty breathing, or rash. Stop the medication and call your doctor immediately.
- •Some medications can increase the risk of cardiovascular events. Tell your doctor if you have high blood pressure, a history of heart attack or stroke, or any pre-existing health condition.
- •Avoid or limit alcohol while taking Semaglutide (Oral). Do not drink alcohol without first discussing it with your healthcare provider as it may increase adverse effects.
- •Take Semaglutide (Oral) with food or a full glass of water if stomach upset occurs. Stop use and talk to your doctor if you experience persistent stomach pain or GI symptoms.
- •Tell your doctor about all medications, supplements, and vitamins you take. Some combinations significantly increase the risk of harm.
This is a summary only. Always read the full prescribing information and consult your healthcare provider for personalized medical advice.
Uses & Indications
Semaglutide (Oral) is prescribed for the following conditions. Some uses are FDA-approved indications; others may be evidence-based off-label uses. Consult your healthcare provider for personalized guidance.
Type 2 diabetes mellitus (glycemic control)
Cardiovascular risk reduction in type 2 diabetes
Dosage Guide
The following are general dosing guidelines only. Your actual dose should be determined by your healthcare provider based on your condition, renal/hepatic function, and other medications.
AD
Adult Dosage
Oral (Rybelsus): Start 3 mg once daily for 30 days, increase to 7 mg once daily, then to 14 mg once daily if needed. Injectable (Ozempic): Start 0.25 mg SC once weekly for 4 weeks, increase to 0.5 mg weekly; may increase to 1–2 mg weekly.
PD
Pediatric Dosage
Not approved for pediatric use.
RI
Renal Impairment
No dose adjustment required for mild-moderate renal impairment.
HI
Hepatic Impairment
No dose adjustment required.
Available Forms
Oral tablet (Rybelsus)Subcutaneous injection pen (Ozempic)
Available Strengths
3 mg (oral)7 mg (oral)14 mg (oral)0.25 mg/dose (injection)0.5 mg/dose (injection)1 mg/dose (injection)2 mg/dose (injection)
Side Effects
Common
- Nausea
- Diarrhea
- Vomiting
- Abdominal pain
- Decreased appetite
- Constipation
Serious
- Acute pancreatitis
- Diabetic retinopathy complications
- Hypoglycemia (with insulin/sulfonylureas)
- Acute kidney injury (from volume depletion)
- Severe GI adverse reactions
Rare
- Medullary thyroid carcinoma (theoretical)
- Acute gallbladder disease
- Anaphylaxis
Medicine Interactions
Always inform your healthcare provider and pharmacist about ALL medications you take, including prescriptions, OTC medicines, vitamins, and supplements.
MajorModerateMinor
major
Insulin
Concurrent insulin substantially increases hypoglycemia risk.
Management: Reduce basal insulin dose by 20–30% when adding semaglutide; monitor glucose.
moderate
Sulfonylureas (glipizide, glyburide, glimepiride)
Additive insulin secretagogue action raises hypoglycemia risk, particularly in fasting.
Management: Halve the sulfonylurea dose at initiation; titrate based on response.
major
Other GLP-1 receptor agonists (liraglutide, dulaglutide, exenatide)
Combining semaglutide with another GLP-1 agonist duplicates the mechanism, adding GI toxicity without benefit.
Management: Contraindicated — never combine GLP-1 agonists.
moderate
Warfarin
Semaglutide's effect on gastric emptying can unpredictably alter warfarin absorption.
Management: Monitor INR frequently during dose titration and after reaching maintenance dose.
moderate
Oral contraceptives / levothyroxine
Delayed gastric emptying may reduce or delay oral drug absorption.
Management: Take time-sensitive oral medications at least 1 hour before the semaglutide injection day.
moderate
Alcohol
May worsen nausea and vomiting. Can also contribute to delayed gastric emptying.
Management: Advise limiting alcohol, especially during the dose-escalation phase.
Warnings & Contraindications
⚠ Boxed Warning
BLACK BOX WARNING: Risk of thyroid C-cell tumors. Contraindicated in patients with personal/family history of medullary thyroid carcinoma or MEN2.
Risk of acute pancreatitis — discontinue if suspected.
Diabetic retinopathy complications reported in cardiovascular outcomes trials.
Hypoglycemia risk when combined with insulin secretagogues or insulin.
Acute kidney injury from dehydration secondary to GI side effects.
Pulmonary aspiration risk during general anesthesia — inform anesthesiologist before surgery.
How Semaglutide (Oral) Works
Semaglutide is a GLP-1 receptor agonist with 94% sequence homology to native human GLP-1. It activates GLP-1 receptors in the pancreas, liver, and brain — stimulating glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite via central mechanisms.
Pharmacokinetics
Absorption
Oral: absolute bioavailability ~1%, facilitated by the absorption enhancer SNAC; peak at 1 hour. Injectable: peak in 1–3 days after SC injection.
Half-Life
Approximately 7 days (both oral and injectable formulations).
Metabolism
Proteolytic cleavage of the peptide backbone and sequential beta-oxidation of the fatty acid side chain.
Excretion
Renal (~3% unchanged) and fecal excretion of metabolites.
Pregnancy & Breastfeeding Safety
Not classified
Breastfeeding
Many medications pass into breast milk in varying amounts. Before using Semaglutide (Oral)while breastfeeding, discuss the benefits and risks with your healthcare provider or pharmacist — they can weigh your dose, your infant's age, and available lactation safety data to find the safest option for you and your baby.
Storage & Handling
Oral tablets: store at room temperature 20–25°C; keep original package. Injectable: refrigerate 2–8°C until first use; after first use, store at room temperature ≤30°C for up to 56 days.
Frequently Asked Questions
Related on MedCentralHub
- Class hub
GLP-1 Receptor Agonist alternatives
Compare all GLP-1 Receptor Agonist medications — uses, side effects, and cost differences
- Detail
Semaglutide (Oral) dosage guide
Adult, pediatric, renal, and hepatic dosing for Semaglutide (Oral)
- Detail
Semaglutide (Oral) side effects
Complete adverse effect profile including common, serious, and rare reactions
- Detail
Semaglutide (Oral) drug interactions
Full interaction list with severity ratings for Semaglutide (Oral)
- Interaction
Semaglutide (Oral) and Insulin interaction
Check the clinical significance of combining Semaglutide (Oral) with Insulin
- Interaction
Semaglutide (Oral) and Other GLP-1 receptor agonists (liraglutide, dulaglutide, exenatide) interaction
Check the clinical significance of combining Semaglutide (Oral) with Other GLP-1 receptor agonists (liraglutide, dulaglutide, exenatide)
Sources & References
- • FDA Prescribing Information — Official labeling and package insert for Semaglutide (Oral)
- • U.S. National Library of Medicine — MedlinePlus drug information
- • American Hospital Formulary Service (AHFS) — Clinical pharmacology monograph
- • PubMed / MEDLINE — View clinical studies
Last reviewed by MedCentralHub Medical Review Board · MedCentralHub Editorial Policy
Medical Disclaimer
The information on this page is for educational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult your doctor, pharmacist, or qualified healthcare provider before starting, stopping, or changing any medication.